Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 3.70 INR
Change Today 0.00 / 0.00%
Volume 0.0
RBM On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:00 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

rubra medicaments ltd (RBM) Snapshot

Open
3.70
Previous Close
3.70
Day High
3.70
Day Low
3.70
52 Week High
02/24/15 - 4.40
52 Week Low
04/7/14 - 0.96
Market Cap
20.2M
Average Volume 10 Days
1.0
EPS TTM
-0.11
Shares Outstanding
5.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RUBRA MEDICAMENTS LTD (RBM)

Related News

No related news articles were found.

rubra medicaments ltd (RBM) Related Businessweek News

No Related Businessweek News Found

rubra medicaments ltd (RBM) Details

Rubra Medicaments Limited does not have significant operations. Previously, the company was engaged in the manufacture and sale of pharmaceutical formulations. The company was incorporated in 1991 and is based in Hyderabad, India.

Founded in 1991

rubra medicaments ltd (RBM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rubra medicaments ltd (RBM) Key Developments

Rubra Medicaments Ltd Appoints Dinesh Nayak as Director

Rubra Medicaments Ltd. announced that the Board of Directors of the company at its meeting held on March 05, 2015 has appointed Mr. Dinesh Nayak as Director of the company.

Rubra Medicaments Ltd., Board Meeting, Mar 05, 2015

Rubra Medicaments Ltd., Board Meeting, Mar 05, 2015. Agenda: To consider the appointment of Mr. Dinesh Nayak as director of the company.

Rubra Medicaments Ltd. Announces Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Rubra Medicaments Ltd. announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported loss from ordinary activities before other income, finance costs and exceptional items was INR 0.161 million compared to INR 0.162 million a year ago. Loss from ordinary activities before tax was INR 0.161 million compared to INR 0.162 million a year ago. Net loss for the period was INR 0.161 million compared to INR 0.162 million a year ago. For the nine months, the company reported loss from ordinary activities before other income, finance costs and exceptional items was INR 0.554 million compared to INR 0.427 million a year ago. Loss from ordinary activities before tax was INR 0.554 million compared to INR 0.427 million a year ago. Net loss for the period was INR 0.554 million compared to INR 0.427 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBM:IN 3.70 INR 0.00

RBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RBM.
View Industry Companies
 

Industry Analysis

RBM

Industry Average

Valuation RBM Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RUBRA MEDICAMENTS LTD, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.